

Characteristics and outcomes of cryptococcosis among patients with COVID-19 compared to non-COVID-19 controls

Address correspondence to:
Daniel B. Chastain, Pharm.D. BCIDP, AAHIVP
daniel.chastain@uga.edu




Daniel B. Chastain, Vanessa M. Kung, Sahand Golpayegany, Brittany T. Jackson, Carlos Franco-Paredes, Lilian Vargas Barahona, George R. Thompson III, Andrés F. Henao-Martínez

Authors of this presentation have nothing to disclose.

STUDY POPULATION

Patients ≥ 18 years with cryptococcosis based on ICD-10-CM diagnosis codes from TriNetX on May 2, 2022




BASELINE CHARACTERISTICS


	Cryptococcosis following COVID-19	Cryptococcosis without COVID-19	p value
Age (years)	55.2 ± 14.4	51.9 ± 15.2	0.0005
Male sex	68%	69%	0.7108
White	56%	55%	0.6959
Black or African American	24%	25%	0.9405
Non-Hispanic	73%	65%	0.0049
HIV	30%	31%	0.5482
Transplant	29%	13%	<0.0001
Neoplasm	37%	21%	<0.0001
CKD	42%	18%	<0.0001
Type 2 DM	35%	19%	<0.0001
CD4 cells (cells/μL)	104 ± 139	167 ± 292	0.3230
Prednisone	32%	15%	<0.0001
Dexamethasone	17%	7%	<0.0001

RESULTS


Mortality: *no significant difference*




Hospitalization: *significant decrease in patients with COVID-19*




Mechanical ventilation: *no significant difference*




ICU: *significant increase in patients with COVID-19*



Corticosteroids: *significant increase in patients with COVID-19*



Tocilizumab: *significant increase in patients with COVID-19*



OR, odds ratio; PSM, propensity score-matched analysis

In this multicenter research network study of patients with cryptococcosis, 4.5% had COVID-19 prior to cryptococcosis with higher rates of comorbidities, corticosteroid use, and ICU admission, but similar mortality vs those without COVID-19